Pharmacokinetic Drug Dosing Regimen Devices and Methods

A technology of pharmacokinetics and dosing regimens, applied in the direction of drugs or prescriptions, drug combinations, medical equipment, etc., can solve problems such as stress

Active Publication Date: 2020-06-19
TAKEDA PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Every day or every two days regimen stresses the patient by requiring relatively frequent infusions
Every day or every two days regimen may also be unnecessary for some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmacokinetic Drug Dosing Regimen Devices and Methods
  • Pharmacokinetic Drug Dosing Regimen Devices and Methods
  • Pharmacokinetic Drug Dosing Regimen Devices and Methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043] The present invention relates generally to methods, systems and devices for providing drug dosing regimens, and in particular providing pharmacokinetic drug dosing regimens based on models of the pharmacokinetic profile of a sampled patient. The pharmacokinetic drug dosing regimens described herein provide cost-effective use of therapeutic plasma proteins that can be tailored to individual patients. Thus, the exemplary pharmacokinetic drug dosing regimens described herein provide healthcare providers with the ability to achieve relatively rapid and accurate patient dosing without having to determine a patient-specific pharmacokinetic profile based (only) on blood tests suggested tool. The invention also encompasses coagulation factor FVIII products modified to prolong the mean residence time in patients beyond that of native FVIII, for example via the use of water soluble proteins or FC fusion technology, with dosing schedules / intervals longer than three days.

[0044]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A system and method for providing a therapeutic plasma protein dosing regimen includes determining a patient's pharmacokinetic profile using a Bayesian model of the sampled patient's pharmacokinetic profile. The example systems and methods also include determining a first dosing regimen for a first prescribed dosing interval comprising (i) a first dose and (ii) the patient over a period of time based at least on the pharmacokinetic profile. and determining a second dosing regimen for a second prescribed dosing interval comprising (i) a second dose and (ii) at least based on said pharmacokinetic profile over said time The second therapeutic plasma protein level in the patient described in paragraph. The example systems and methods further include displaying the first dosing regimen and the second dosing regimen on a client device such that the first dosing regimen is displayed in conjunction with the second dosing regimen.

Description

Background technique [0001] Factor VIII is a blood clotting protein that is activated in response to injury or bleeding. Individuals with relatively low levels of factor VIII are predisposed to prolonged internal or external bleeding episodes resulting from injury and / or unexplained spontaneous bleeding. Although skin bleeding is not serious, internal bleeding in joints, muscles, and organs can cause permanent damage, disfigurement, or even death. [0002] People with hemophilia A have a genetic defect that causes low levels of clotting factor VIII. The amount of factor VIII in the patient is expressed as a percentage relative to normal levels. Patients with 5% to 40% factor VIII are considered to have mild hemophilia A, while patients with 1% to 5% factor VIII are considered to have moderate hemophilia A. Patients with less than 1% factor VIII are considered to have severe hemophilia A. [0003] Treatment of patients with hemophilia A (or patients otherwise having low lev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): B23P17/04A61M5/31G16B5/20G16H20/10
CPCG16B5/00G16C99/00G16C20/30A61P7/04G16B40/20G16B40/30G16B20/50G16B5/20G16H20/10G16H10/40G16H40/63G16H50/70
Inventor 亚历山德拉·洛-巴塞利杰拉尔德·迪基·施波茨明信·欧
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap